white → pink1 → red1 → purple1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
WARNINGDANGER OF DEATH
High doses alone or ordinary doses in combination with other depressants can fatally stop breathing.
Tapentadol
3-(3-Dimethylamino-1-ethyl-2-methylpropyl)phenol
Nucynta, Palexia, Yantil, Palexia SR, Nucynta ER
Tapentadol is a centrally-acting synthetic opioid analgesic of the phenylpropylaminopentane class. First approved by the FDA in 2008,1 it possesses a dual mechanism of action as both a mu-opioid receptor agonist and norepinephrine reuptake inhibitor.2 Its analgesic potency falls roughly between tramadol and morphine. Tapentadol carries a high addiction potential and significant risk of respiratory depression in overdose;citation needed combining it with other depressants or stimulants is strongly discouraged.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~25 mg
Light25-50 mg
Moderate50-75 mg
Strong75-150 mg
Heavy150+ mg
Bioavailability
~32%
Intranasal administration of tapentadol is not an effective route of delivery.
Duration3
Onset32 minutes
Come Up30-45 minutes
Peak1-2 hours
Offset2-3 hours
After Effects1-12 hours
Total4-6 hours
Half-life
~4 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
The experience is dominated by the classic opioid profile of pain relief, physical relaxation, and mood elevation, with little in the way of sensory alteration. Euphoria and a general lift in mood accompany the analgesia, while the body settles into a relaxed, sedated state. Compared to purely sedating opioids, the headspace tends to remain relatively functional at therapeutic doses, though somnolence becomes prominent as the dose increases.
Physical
Physical relaxation and analgesia define the body experience, alongside typical opioid side effects such as itchiness, dry mouth, constipation, and constricted pupils. Respiratory depression is a dose-dependent risk that becomes dangerous at high doses.
Sedation
Cognitive
The mental state is characterized by euphoria and an elevated, contented mood. At higher doses this gives way to increasing drowsiness and mental clouding, progressing toward stupor in overdose.
Emotional
Pharmacology
Pharmacodynamics
Tapentadol acts through a dual mechanism as a full agonist at the μ-opioid receptor (MOR) and as a norepinephrine reuptake inhibitor.citation needed It demonstrates high selectivity for MOR, with at least ten-fold greater affinity compared to δ- and κ-opioid receptors. In receptor binding studies, tapentadol has a Ki of 60 nM at human MOR and a Ki of 480 nM for norepinephrine reuptake inhibition, with agonist activity comparable to morphine despite approximately one-third the binding affinity. Tapentadol also weakly inhibits serotonin reuptake, though this action does not appear to contribute to its analgesic effect.
Pharmacokinetics
Tapentadol has a mean oral bioavailability of approximately 32% due to extensive first-pass metabolism.4 It is predominantly metabolized through Phase II conjugation pathways, primarily glucuronidation, with the O-glucuronide representing the major metabolite (approximately 55% of urinary excretion) and a sulfate conjugate accounting for roughly 15%.4 Phase I oxidative metabolism plays a minor role: CYP2C9 and CYP2C19 mediate demethylation to N-desmethyl tapentadol (about 13% of the dose), while CYP2D6 mediates hydroxylation to hydroxy tapentadol (about 2%).4 None of tapentadol's metabolites are pharmacologically active.citation needed The terminal elimination half-life is approximately four hours after oral administration, with tapentadol and its metabolites almost entirely excreted through the kidneys.4
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
1,2-BenzodiazepineAcenocoumarolAcetazolamideAcetophenazineAclidinium
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the analgesic and euphoric effects develops with repeated use, as is characteristic of μ-opioid receptor agonists. The rate of tolerance development varies between individuals and is influenced by dosing frequency and duration of use.
Cross Tolerance
Opioids (morphine, oxycodone, hydromorphone, fentanyl, and other μ-opioid receptor agonists)
Harm Potential
Addiction & Dependence
Psychological
HighTapentadol has high abuse potential comparable to other strong μ-opioid receptor agonists such as morphine, oxycodone, and hydromorphone.citation needed It is commonly abused, misused, and diverted; human abuse liability studies found 50 mg of tapentadol produces opioid effects comparable to 4 mg of hydromorphone. Its water solubility enables abuse via snorting, inhaling, or injection, which significantly increases risk of dangerous consequences.
Physical
HighPhysical dependence develops with regular use, and withdrawal symptoms may be more intense and prolonged compared to typical opioids such as codeine or oxycodone due to tapentadol's dual mechanism as both an opioid agonist and norepinephrine reuptake inhibitor. Withdrawal symptoms include anxiety, restlessness, fever, chills, joint pain, nausea, vomiting, stomach cramps, sweating, tremor, and insomnia.citation needed Gradual tapering is recommended rather than abrupt cessation.
Toxicity
Respiratory
Respiratory depression is the primary life-threatening toxicity and occurs through direct suppression of brainstem respiratory centers; this effect is dose-dependent and represents the main cause of death in overdose.citation needed
Cardiovascular
Hypotension and bradycardia may occur, particularly at higher doses or in overdose situations; these effects are generally manageable with supportive care.citation needed
Gastrointestinal
Reduced gastrointestinal motility commonly results in constipation, nausea, and vomiting during therapeutic use; studies indicate tapentadol causes less constipation and nausea compared with oxycodone.citation needed
Seizure Risk
Tapentadol has been demonstrated to reduce the seizure threshold and is contraindicated in people with epilepsy or who are otherwise prone to seizures. Risk is elevated in patients with head trauma, metabolic disorders, or those undergoing alcohol and drug withdrawal.
History & Culture
Discovery and Development
Tapentadol was developed by the German pharmaceutical company Grünenthal during the late 1980s.citation needed The research team, led by chemist Helmut Buschmann, used tramadol as their starting point, a compound the same company had created in 1962. Their objective was to design…
Legality
By Country
Controlled / restricted1
United StatesRestricted21 CFR § 1308.12(c)(29)12
Approved by the FDA on November 20, 2008,13 with the extended-release formulation receiving approval on August 26, 2011.14 Classified as a narcotic analgesic with recognized high potential for misuse and abuse.156 Due to addiction risks, tapentadol is reserved for patients for whom alternative treatment options are inadequate or unavailable.15
Prescription1
GermanyPrescription onlyTapentadol is expressly listed in Schedule III (Anlage III) of Germany's Narcotics Act under its INN and chemical name. Schedule III substances are controlled narcotics that may be prescribed by physicians, dentists, or veterinarians only when their use is justified; pharmacy dispensing requires a prescription. The schedule also covers salts, molecular compounds, and preparations of listed substances subject to its stated exceptions.
References
Source Pages
Citations
- NUCYNTA (tapentadol hydrochloride) tablet, film coated — DailyMed Label. (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00A8921E-46A6-4DF1-A744-9E532B6FB06F1
- Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. (n.d.). https://pubmed.ncbi.nlm.nih.gov/21476608/1
- Structured oral dosage and duration reference page. psychonautwiki.org (n.d.). https://psychonautwiki.org/wiki/Tapentadol1
- NUCYNTA (tapentadol hydrochloride) tablet, film coated — Full Prescribing Information. Collegium Pharmaceutical, Inc. (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7997e6da-7e98-4520-9d1b-0b8341bac64a1234
- NUCYNTA ER (tapentadol hydrochloride) extended-release tablet — Full Prescribing Information. Collegium Pharmaceutical, Inc. (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3d04d70-0155-4147-9ce4-a3b1fad4b3731
- Schedules of Controlled Substances: Placement of Tapentadol Into Schedule II. Federal Register, 74(97) (May 21, 2009). https://www.govinfo.gov/content/pkg/FR-2009-05-21/html/E9-11933.htm123
- FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy. (August 29, 2012). https://www.prnewswire.com/news-releases/fda-approves-nucynta-er-tapentadol-extended-release-oral-tablets-for-the-management-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy-167814965.html1
- Depomed Buys U.S. Rights to Nucynta Franchise for $1.05B. (January 2015). https://www.genengnews.com/topics/drug-discovery/depomed-buys-u-s-rights-to-nucynta-franchise-for-1-05b/1
- Betäubungsmittelgesetz (BtMG), Anlage III. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html1
- Betäubungsmittelgesetz (BtMG), Anlage III. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/__1.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
16 August 2026
Lyrea · Reworded 2 words in History & Culture › Sections 1 › Content
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Tapentadol article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.